AZTR Stock Overview
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Azitra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$5.18 |
| 52 Week Low | US$0.16 |
| Beta | 0 |
| 1 Month Change | 10.74% |
| 3 Month Change | -80.63% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZTR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.09% | 0.5% | -0.7% |
| 1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how AZTR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AZTR performed against the US Market.
Price Volatility
| AZTR volatility | |
|---|---|
| AZTR Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AZTR's share price has been volatile over the past 3 months.
Volatility Over Time: AZTR's weekly volatility has increased from 20% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Francisco Salva | azitrainc.com |
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.
Azitra, Inc. Fundamentals Summary
| AZTR fundamental statistics | |
|---|---|
| Market cap | US$6.39m |
| Earnings (TTM) | -US$12.64m |
| Revenue (TTM) | US$686.00k |
9.4x
P/S Ratio-0.5x
P/E RatioIs AZTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZTR income statement (TTM) | |
|---|---|
| Revenue | US$686.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$686.00k |
| Other Expenses | US$13.33m |
| Earnings | -US$12.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,842.44% |
| Debt/Equity Ratio | 0% |
How did AZTR perform over the long term?
See historical performance and comparison